LMP-420 is a selective inhibitor of tumor necrosis factor-α (TNF-α). It reduces the release of pro-inflammatory cytokines, such as IL-1β and IL-2, while inducing the expression of anti-inflammatory cytokine IL-10, and anti-apoptotic molecules SOCS-1 and Mn-SOD. LMP-420 also downregulates chemokines like IP-10 and MCP-1, which decreases immune cell infiltration. This compound shows potential for research into type 1 diabetes, inflammatory diseases such as colitis, and HIV-mycobacterium tuberculosis co-infection.